methods , systems , and apparatus according to the present invention rely on placement and use of one or more anchoring and injection / aspiration elements positioned at or within a treatment region of a patient . the treatment region may be located anywhere in the body where fluid injection / aspiration may be beneficial . most commonly , the treatment region will comprise a solid tumor within an organ of the body , such as the liver , kidney , lung , bowel , stomach , pancreas , breast , prostate , uterus , muscle , brain . the volume of fluid - based substance to be injected depends on the size of the tumor or other lesion , typically having a total volume from 1 cm . 3 to 150 cm . 3 , usually from 1 cm . 3 to 50 cm . 3 , and often from 2 cm . 3 to 35 cm . 3 . the peripheral dimensions of the treatment region may be regular , e . g . spherical or ellipsoidal . however , typical tumor shape is irregular . the treatment region may be identified using conventional imaging techniques capable of elucidating a target tissue , e . g . tumor tissue , such as ultrasonic scanning , magnetic resonance imaging ( mri ), computer - assisted tomography ( cat ), fluoroscopy , nuclear scanning ( using radio labeled tumor - specific probes ), and the like . high - resolution ultrasound or ct can be employed to monitor the size and location of the tumor or other lesion being treated , intraoperatively or externally . the treatment region may also be identified with sensors for sensing tissue parameters such as electrical impedance , temperature , pressure , and optical characteristics disposed at the distal end of the indwelling self - anchoring catheter on injection / aspiration needle . one or more sensors may be used in any desirable combination and disposition over the indwelling end of the self - anchoring catheter or needle . in an illustrative embodiment , the present invention generally provides a tissue - anchoring , fluid delivery and aspiration system , and preferably a fluid delivery system for delivering cytotoxic drugs to the interstitial space of solid tumor tissue . while the system can be used for a variety of purposes , it is preferably used to treat soft tissue tumors under ultrasound guidance in order to minimize exposure to radiation and reduce cost associated with the procedure . although the preferred embodiment describes a catheter - like device , it is contemplated within the invention that the features described apply to needle , cannulas , and other needle - like devices . as illustrated in fig1 a and 3 , the self - anchoring , backflow limiting device includes a multilumen catheter member 10 . multilumen catheter 10 has a proximal end 12 , a distal end 13 , an inner lumen 150 extending through , and a cryogenically induced region ( or anchoring member ) 19 . at least one cryogenically induced region and injection lumen includes a means for occlusion of the instrument entry track into the tissue and an injection opening 160 located at or distal to the cryogenically induced region . the multilumen catheter is comprised of a shaft 11 . inner lumen 150 of the multilumen catheter 10 has adjacent multiple lumens ( 15 , 16 , 17 ) as illustrated by fig1 a and 1b . the distal end 13 of catheter member 10 and / or the cryogenically induced region inner and / or outer wall 140 is optionally equipped with sensing members 18 . sensor members 18 are electrically coupled to a data logger ( not represented ), a controller , and monitoring system ( not represented ). the catheter 10 has fluid control means ( aspiration , injection ) at the proximal end 12 through tubing 120 , and cryogenic fluid control means with controller 23 through tubing 230 . quick connectors at proximal ends of tubing 120 and 230 allow for an instant disconnection of the catheter member that is readily interchangeable and may be provided as a disposable element of the invention . the distal end 13 of the catheter 10 may be steerable by conventional means . alternatively , the distal end may be of a flexibility , toughness , and formability differing from that of shaft 11 . the tip end 14 is preferably closed , blunt or tapered or round , but may be of any desirable shape , flexibility and openness like pointed , sharp , cutting , fully open , pre - bent , or bendable , and / or steerable . such metal as stainless steel , titanium , platinum or metallic alloy , or memory material like nitinol may be used for its structure . tip 14 , or a portion thereof , may also be constructed of any material , such as but not limited to radio opaque material , capable of being used for radiography or fluoroscopy purposes . any desirable combination of toughness , slidability , or flexibility and other desirable characteristics for the proximal end 12 and distal end 13 of catheter 10 is within the spirit of the invention . proximal end 12 has two extension members 120 and 230 ; extension member 120 comprises two separate tubings 121 and 122 , see fig3 . tubing 122 is coupled to inner lumen 17 of catheter 10 and more particularly to inner lumen 40 which fluidly communicates with opening ports 170 located at distal end 13 of catheter tip end 14 . tubing 121 fluidly communicates with inner lumen 16 . lumen 16 is in fluid communication with opening port 160 at tip end 14 . opening ports 160 and 170 are located distal to or at the level of the cryogenically induced region or anywhere along tip of distal end to allow for desirable injection - aspiration patterns . opening ports 160 and 170 may be located proximal to an cryogenically induced region when distal end 13 comprises more than one cryogenically induced region as illustrated in fig3 , the proximal end of tubing 121 is connected to a pressurized fluid source 22 , for instances a syringe or a pump ( not represented ) well known to one of ordinary skill in the field . the pressurized fluid source provides a means to inject , at a controlled rate and pressure , at least one fluid ( composition and / or tissue fluid ) of interest . fig3 also illustrates the proximal end of tubing 122 connections to a vacuum source 21 , for instances a syringe or a pump ( not represented ) well known to one of ordinary skill in the field . the vacuum source provides means to aspirate , at a controlled rate and pressure , at least one fluid ( composition and / or tissue fluid ) of interest . it is contemplated that tubing 121 , 122 and openings ports 160 , 170 can be used interchangeably as injection and / or aspiration members if they are connected to the corresponding vacuum and pressurized sources that can be used sequentially or simultaneously through a manifold 50 ( see fig3 ). for instances , a 4 - way manifold ( not detailed here ) could allow for a multiplicity of operations , including but not limited to aspirating fluids and waste , injecting , separately or in conjunction , composition and / or other desirable agents , such as but not limited to contrast medium , hot or cold fluids , sealing substances . moreover , a single tubing can be used as an injection and aspiration means . fig2 illustrates an alternative embodiment of the invention . in addition to tumors , the multilumen catheter can also be used to treat areas of the body such as a vascular or organ lumen . as illustrated , the multilumen catheter is percutaneously introduced into vein lumen 211 through vein wall 210 . as further depicted , the multilumen catheter has two cryogenically induced regions 19 ′ and 19 ″. injection of a treatment composition , such as , but not limited to a sclerosant , is accomplished through lumen 16 . the formation of the two cryogenically induced regions allows the substance to remain at the site of deposition without being diluted or washed out by blood flow . although the tip 14 is illustrated as being closed , it is within the invention that the tip also includes one or more openings . the formation of each cryoseal can be phased to alternate with each other . percutaneous approach and vascular access is made easier with the adjunct of the echogenic enhancement of the vibrating driver ( colormark & amp ; nuvue colormark , critical care innovations , inc ). fig4 a illustrates another alternative embodiment of the invention , comprising a single tubing 16 and distal end opening 160 , similar to that of fig1 , along with a single cryogenically induced region 19 proximal to opening 160 . fig4 a and 4b show injecting lumen 16 located parallel and adjacent and in slidable contact or arrangement with the outer wall surface of catheter shaft 11 and distal end 13 . distal end opening 160 of lumen 16 is represented protruding off the distal end of tip 14 , illustrating a means for adjusting depth of immersion of distal end of injection / aspiration tubing 16 out of sliding channel 161 . the cryogenic element of the invention includes one or more cryogenic elements of the invention which plays a role in providing the cooling effect associated with the anti - flow back cryogenically induced region . as depicted in fig3 , extension member 230 of proximal end 12 communicates with lumen 15 and 150 of distal end 13 . lumen 15 provides cryogenic fluid at high or low pressure to chamber lumen 150 whose bottom defines level of wall 140 cooling zone and location of cryogenically induced region interface ( frozen / unfrozen layer ). the location of bottom wall 151 of chamber 150 defines the level , dimension and shape of cryogenically induced region , thus resulting ranges of size and shape . the location of cryogenically induced region defines the length of working member of catheter distal end 13 . optional conduit 141 runs along shaft longitudinal axis within wall thickness of shaft 11 and may couple sensors ( thermal , pressure , impedance ) 18 with signal data loggers ( not represented ) through electrical wires , optical fibers , or any coupling cable for signal transmission known to the field . extension member 230 is connected with a quick pneumatic / electric connector 25 to controller 23 and to a cryogenic source gas cylinder 24 . although the cryogenic source 26 is illustrated as having a gas phase 27 and liquid phase 28 , any liquid refrigerant and refrigerant system is contemplated for use within the invention . gas cylinder 24 may contain a cylinder valve 29 . controller 23 contains modules for converting signals from sensors into readable parameters , such as , but not limited to , temperature or resistivity of cooling zone and tissue interface , for monitoring and controlling operation of catheter . controller may include indicators for temperature indicator 231 , timer 232 and / or setting for cryoseal duration , pressure regulator 233 , pressure gauge 234 , power switch 235 . parameters can be displayed on a controller screen and / or on a separate display screen such as a computer using specific software . controller may also display anchoring member temperature , time , initiation or termination of anchoring , pressure within cryogenic tubing . although depicted near controller 23 , gas outlet 150 may be located in other areas . in another illustrative embodiment of the invention , fig5 a depicts a self - anchoring cannula where channel 16 is an operative channel that accommodates and allows various sliding applicators or guides 41 for cannula guidance and / or tissue operation . the cannula tip end 14 comprises the distal lumen opening 160 , which is equipped with a valve 30 . valve 30 may be a haemostatic valve or be constructed of self - sealing silicone plug . any other sealing material which can be used as a plug is contemplated within the invention . the plug seals the cannula distal end against hydrostatic pressure , but allows passage of a needle , probe , balloon catheter or any tissue operative instrument known to those in the art , by way of a slit , for operation . plug seal 30 resiliently closes after removal of instrument . facultative plug or haemostatic valve 30 may be located at proximal and / or distal end of lumen 16 . fig5 b is a magnification of 41 and illustrates the multi - needle slidable applicator protruding off anchoring tip 14 which is deployed in operative mode for a better distribution of injectable composition . the applicators are constructed and designed to be variable in length as well as being capable of being deployable in situ . tip end applicators 41 are optionally equipped with sensors 18 and can be used to provide energy sources , fluids , mechanical devices , guide wires , or the like , to the tissue . it is contemplated that injection and / or aspiration lumen , such as illustrated in fig1 , would add functionality to the anchoring cannula . it is also within the spirit of the invention that retractable , adjustable length , and deployable fluid , balloon catheter or needle , energy and / or operating tip ends and / or mechanical devices may be used in conjunction with any of the devices embodied within the invention . in a non - limiting illustrated example , fig5 b depicts applicators which are variable in length . several of the applicators are positioned within frozen margin of a seal 193 while several other applicators are illustrated as extending to unfrozen region 194 . the catheter and lumen are made of plastic , and or composite materials that are compatible with critical parameters such as pressure , profile , yield , and compatibility with composition , pushability , flexibility , kink and torque resistance , sterilization and the like . they should also be able to incorporate wires and microcomponents such as sensors or optical systems . a number of materials are available for catheter and thin wall miniature tubing construction , including , but not limited to , polyethylene ( pet ), nylon , pe ( cross linked and other polyolefin ), polyurethane , polyvinyl chloride ( pvc ), and composite - like materials ( polyamide / polyurethane composite ), polyurethane teco polymers , poly ( tetrafluoroethane ) or poly ( tetrafluoroethylene ) ( ptfe ), pebax , hytrel , polyimide , and braided polyimide . size of catheter or needle : the outer diameter of the shaft 11 could range in size , for example , from 0 . 3 mm for microprocedures , to 2 . 5 mm for endoscopic procedures , to 10 mm or more for open surgery procedure or direct procedures through natural openings or surgical cavities . the length of the shaft depending on the location of tissue from the body surface could be in the range of , for example , 15 cm for easily accessible tissue such as the prostate gland to 130 cm or up to 200 cm for endoscopic procedure to distal lesion of the aerial , or digestive tract . in a needle injector embodiment of fig4 a , the cooling zone was determined to have a height of 70 mm , diameter of cooling tip of fr . 3 , diameter of adjacent slidable metal needle of 24 g , and diameter of adjacent thermocouple teflon wire of 1 mm . all three parts were in close contact with each other within a ptfe sheath of 2 . 7 mm diameter . using this prototype inserted into a chicken leg , a digital thermometer fluke 54ii ( fluke , usa ), and a tissue biocompatible marker ( spot , gi supply , inc , usa ), injection procedure was effected at slightly negative temperature (− 3 ° c .) of the ring - shaped cryoseal to tissue interface , even though freezing point of spot is 0 ° c . cryogen was co 2 from a high - pressure cylinder . warming was spontaneous . in the catheter injector embodiment of fig4 a , diameter of distal cooling tip was fr . 8 and height of 10 mm . the injecting tip opening was at a level of the cooling tip distal end with the metal injecting tubing at 24 g . injection procedure was possible during warming of indwelling catheter injector when wall temperature was slightly positive ( start + 3 ° c .) and maintained at that level during the rest of the spot marker injection . no backflow of the marker though the entry - track of the catheter was detected when the cryoseal was “ on .” control tests indicated that backflow was present during injection in the absence of the cryoseal . there was no need for injection opening of adjacent injection tubing 16 of fig4 a to be protruding for injection to be successful , complete , and without backflow . proximal end of operative channel 16 of fig5 a may be equipped with a means to control the depth of penetration of distal end tip 14 and injection tip end 41 . first cannula shaft and injection stem may bear markings at known distances , and second valve 30 allows for sliding and adjusting depth of penetration of injection stem off the cannula indwelling end . it is obvious that during positioning of the catheter , needle or cannula equipped with the retractable inner needle instrument or device , the inner instrument or device remains retracted during positioning and securing of the cannula to the target , which are then deployed in operative position . critical dimensions of the cryoseal : the frozen and / or unfrozen ring - like shaped tissue layer created longitudinally and radially along the instrument axis and about the cooling zone 152 of injector distal end 14 may vary in size and shape with the thermal field created about the cooling zone . its height may vary from 0 . 5 mm to 50 mm , preferably from 1 mm to 30 mm , and more preferably from 5 mm to 10 mm . its thickness temperature and structure ( among other physicochemical parameters ) may also vary with cooling temperature and duration of application . however , cryothermal and structural change expansion ( thickness ) into tissue is controllable so that only the anti - backflow and / or the anchoring effect are obtained without any damage or harm to surrounding tissue . alternatively lower negative temperatures for the cryoseal or longer duration or activation to the lower temperatures may entail the growth of large , sizeable frozen / unfrozen volumes . if it is estimated that the indwelling part of the catheter has created an irregular and large entry track , the operator may form a larger frozen ring than otherwise would be necessary . however , the preliminary injection of inert contacting fluid , such as isotonic saline liquid , into an irregular entry track through injection openings may circumvent the issue and allow for creation of a small self - adjusted fluid - to - tissue biological cryoseal . although the cryoseal is made of structured water and tissue components at various temperatures that seal and bond the indwelling cooling wall of fixed dimensions to the tissue , the cooling zone of wall 152 may be sizeable . for instance , such cooling zone may be that of an inflatable cooling balloon whose interior connects to lumen 15 through a wall opening for the cryogen , and to lumen 150 through a cryogen return opening . although the tip end of device 11 is usually cylindrical and straight any other shape best suited for the intended use , such as such as pigtail , bent , or curved shape is within the scope of this invention . a typical mode of operation , such as for percutaneous image - guided solid tumor tissue injection , utilizing the catheter / needle of the instant invention is as follows : tumor characteristics , such as location , shape , structure , relation to structures or organs , are determined prior to injection so that the guidance technique , the needle path , the type and volume of composition to be injected are precisely calculated . the composition is prepared and ready to use for the indicated procedure . in the first step , the distal end of the device is guided to tumor site ( fig1 ) with appropriate guiding means . a preferred , but non - limiting means includes imaging guidance using ultrasound with an enhanced echogenicity device using colormark or nuvue colormark features ( critical care innovations , inc ). in the second step , the distal end is embedded into tumor tissue 100 through tissue surface 200 at desirable depth and if necessary imaged by an external device 300 such as ultrasound , or assessed by sensors 18 . the third step of the procedure provides for opening of the cryogenic fluid valve of controller 23 ( manual switch , pedal , automated switch ) to allow fluid circulation and / or expansion within lumen 150 . this results in cool down of the wall of indwelling part of injector and creates a cooled ring - like zone made of frozen / unfrozen tissue as the wall temperature drops down to the freezing point temperature of the tumor , i . e . in the range of about + 4 degrees c . (° c .) to − 4 ° c . or lower , preferably 0 ° c . to − 4 ° c ., or lower . given that a thin layer of unfrozen / frozen tissue suffices to create a tight and leak proof bond at the multilumen / tissue interface , there is no need to make a large frozen cryoseal ring when the goal is only to perform an injection or aspiration procedure . the cryogenically induced region is maintained by adjusting the flow of the cryogenic fluid over time so that the cryogenic seal / bond thickness is sustained . the temperature of the wall to seal interface bond is regulated to desirable wall device temperature for flowing substances ( or substance mixture ) to the distal end of the injection lumen ( i . e . temperature is slightly higher than freezing point of substance , or freezing point of substance is slightly lower than that of tissue ). substance can also be mixed with low freezing point fluids . the fourth step includes injection of the composition . injection commences in conjunction with cryoseal formation and is assessed either by immobilization of the tip end or ring / tissue temperature measured or calculated by specific dedicated software , such strength may vary with the nature and hydration of the target tissue . injection may be effected during re - warming of the cryoseal and melting of ice crystals , as long as the bond temperature is still strong enough to insure sealing of entry track 101 of indwelling multilumen catheter 12 . depending on tissue characteristics , indication , volume to be injected , patient cooperation and clinical status , injection may be effected at once and quickly against tissue pressure , lasting only a few seconds , from 1 to 10 seconds . injection may be effected slowly at low pressure over a period of seconds to minutes . injection may last over longer periods if necessary . in any case , the cryoseal is maintained at stable and desirable size for the desirable duration by monitoring and controlling its temperature with cooling / warming ( spontaneous or artificially controlled ) sequences . sequences are based on “ on ” and “ off ” position of cryogenic fluid valve , continuous supply of cryogen at different pressure , or combination of both , or on any other means known by those of skill in the art . injection sites : injection can be performed within warm , cooled , and / or frozen tissue , since the device design allows for adjusting the location of injection openings in relation to tumor characteristics and / or thermal fields . unlimited injections may be executed within pervious tissue structures and be concurrent to a static or a dynamic cryoseal , i . e ., a steady , growing or regressing . it is understood that a previously impervious structure of the cryoseal may be injected with composition when returning to a state of fluid permeability . in the fifth step , the cryogenically induced region is left to warm and / or melt spontaneously or automatically . the cryoseal may melt as soon as the injection is completed . upon spontaneous warming , detachment occurs when the device becomes movable within the tissue or its temperature is above its freezing point . it may be desirable to dislodge and remove the device from the tissue before full melting of the cryoseal . in such a case , warming of the cooling zone may be effected by heating resistance located in the wall of shaft 11 , or by closing a valve located on return lumen 150 . such action prevents further cryogen expansion and permits warm cryogen fluid into lumen 150 . if fractionation of dose or multiple injection sites are a preferred mode of administration , steps 2 to 4 are repeated . if a period is estimated necessary for administered dose to be distributed or absorbed within target tumor , the cryoseal is maintained for such desirable period without further injection . it is further contemplated that the cryogenic fluid flow can be short in duration , alternated with stop flow periods of cool - warm cycles , or continuous over variable duration periods to allow for permanent securing and positioning of the fluid flow device to the target tissue . it is also contemplated that a sizeable cryogenic seal may have a fluid impervious structure and / or a damaging structure and / or a damaging structure for tissue cells or components . by adjusting the temperature ( for instances with low boiling point coolant ) and duration of the cooling / warming cycle and performing one or multiple cycles the deleterious effects of the cryoseal can be associated with the physicochemical effects of the injected fluid - based composition . termination of the cryogenically induced region occurs by preventing cryogenic fluid admission , and melting cryogenic seal to allow for fast detachment of fluid flow device . at termination , the device can be retrieved from the tissue . permanent seal of entry track : it may be desirable to permanently occlude the entry - track of the device after removal . in such case injection lumen 16 allows for injecting tissue with sealing agents , such as but not limited to glue or fibrin glue , during removal of the device . some sealing agents may be selected from substances that are liquid in cold state and solid in warm state . aspiration mode : operator effects step 1 to 3 , then aspirates tissue fluids and or tissue components through the opening 170 of lumen 17 , by way of a mechanism including , but not limited to applying negative pressure at the proximate end of the aspiration lumen . tissue washing mode : operator effects steps 1 to 3 , then injects compositions and simultaneously or sequentially aspirates tissue fragments , debris , cells , and fluids . alternative use of self - anchoring injector : an alternative use of the injector of the invention includes manipulation of the tissue of interest before or during treatment administration such as but not limited to techniques of imaging , ablation , injection , or extirpation . tissue ablation . in addition to methods for creating a self - anchoring , it is contemplated that the anti - flow back device which is capable of injecting compositions into a treatment site can further be used for tissue ablation methods . such tissue ablation techniques may include cryogenics and / or injection of various ablation compositions , such as free drug - solutions or carrier bound drugs . the apparatus of the invention can be combined with any open access and / or minimally invasive ablation techniques ( high intensity focused ablation ( hifu ), microwave , laser light , radiofrequency ( rf ), cryosurgery , brachytherapy ), or loco - regional therapies ( embolization , chemoembolization and the like ), or systemic therapies ( chemotherapies ). all patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains . all patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference . it is to be understood that while a certain form of the invention is illustrated , it is not to be limited to the specific form or arrangement herein described and shown . it will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification and any drawings / figures included herein . one skilled in the art will readily appreciate that the present invention is well adapted to carry out the objectives and obtain the ends and advantages mentioned , as well as those inherent therein . the embodiments , methods , procedures and techniques described herein are presently representative of the preferred embodiments , are intended to be exemplary and are not intended as limitations on the scope . changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims . although the invention has been described in connection with specific preferred embodiments , it should be understood that the invention as claimed should not be unduly limited to such specific embodiments . indeed , various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims .